Cancer Capital CORP
Market Movers (8-K)
Cancer Capital Corp. amended its 8-K filing to correct the name of its new audit firm, Fruci & Associates II, PLLC, after dismissing Pinnacle Accountancy Group of Utah.
Cancer Capital Corp. has dismissed Pinnacle Accountancy Group and engaged Fruci & Associates as its new independent registered public accounting firm, effective November 30, 2023.
Quarterly Earnings (10-Q)
10-Q: Cancer Capital Corp. Reports Third Quarter 2024 Results, Continues Search for Merger Opportunity
Cancer Capital Corp. reports a net loss of $8,436 for the third quarter of 2024 and continues to seek a merger or acquisition target.
Worse than expected
Capital raise
Cancer Capital Corp.'s Q2 2024 filing reveals ongoing losses, minimal cash reserves, and continued reliance on related-party funding, raising substantial doubt about its ability to continue as a going concern.
Worse than expected
Capital raise
Cancer Capital Corp. reported no revenue and a net loss of $15,939 for the quarter ended March 31, 2024, with substantial doubt about its ability to continue as a going concern.
Worse than expected
Capital raise
Annual Reports (10-K)
Cancer Capital Corp.'s 2023 annual report reveals ongoing efforts to identify a suitable business opportunity, with no revenue generated and continued reliance on related-party funding.
Capital raise
Worse than expected